This expanded effort will be conducted at Purdue University’s Bindley Bioscience Center, and will focus on further validating targeted, systemically delivered cancer therapies utilizing Kylin’s proprietary pRNAi platform.
pRNA is a discrete, RNA-based nanoparticle system. Kylin has re-engineered pRNA to induce RNA interference (RNAi). The resulting therapeutic platform is called pRNAi. This platform represents the next generation of RNAi-inducing therapeutics with superior pharmacokinetics and potency over siRNA, said Kylin.
Eric Davis, president and CEO of Kylin, said: “Our in vivo efforts have shown pRNAi to be a very potent and versatile RNA inducing platform. This expanded effort will enable us to test the flexibility of the pRNAi platform against various cancer targets.”